AstraZeneca will pay up to $420M for Moderna's mRNA technology

Moderna Therapeutics granted AstraZeneca five-year exclusive rights to use its messenger RNA technology to develop and market treatments for cancer and other serious diseases. Moderna will receive $240 million upfront and as much as $180 million in milestone fees plus sales royalties. The deal's initial payment is one of the biggest ever in a pharmaceutical licensing agreement that doesn't involve a clinical-stage drug.

View Full Article in:

New York Times (tiered subscription model), The · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ